The FDA handed down a major shock to AstraZeneca yesterday when it rejected its key hyperkalemia drug ZS-9, leaving potential rival Relypsa’s shares to jump in…
Clinicians looking for a reliable, controlled method to treat a host of recovering opioid addicts will now have a new resource in the armamentarium.
It’s a veritable free-for-all market for CROs as yet another contract research group--this time Bioclinica--is said to be seeking a major sale.
A few weeks after the FDA slapped a clinical hold on GlaxoSmithKline’s late-stage work on an experimental drug for a rare cardiac condition, the pharma giant…
A trio of Israeli biotechs have completed the initial filings for IPOs to raise up to $130 million each--but are holding off until demand picks up.
Bavarian Nordic has posted top-line data from a Phase I trial of its respiratory syncytial virus vaccine, setting it up to start larger study later this year.
A startup has picked up a Merck Serono castoff, signed up the R&D chief who axed the drug and set about turning it into a multiple myeloma combo treatment.
The FDA’s diabetes experts provided their second endorsement for a treatment duo in two days, voting 12 to 2 to back Sanofi’s marketing application.
Circassia has initiated an adaptive-design Phase III trial of its grass allergy immunotherapy, setting it up to deliver data in 2018.
Galapagos and Gilead will give 200-mg doses of filgotinib in their upcoming Phase III trial, quashing concerns that testicular toxicity would limit dosing.